Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Vivos Therapeutics, Inc. (VVOS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/16/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/16/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/15/2023 |
4
| Huntsman Ronald Kirk (CEO) has filed a Form 4 on Vivos Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $0.49, valued at
$4.9k
|
|
| 06/08/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/27/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
424B1
| Form 424B1 - Prospectus [Rule 424(b)(1)]: |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"VIVOS THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT Warrant Shares: [_______] Initial Exercise Date: January [__], 2023 Issue Date: January, [__], 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on July 5, 2028 but not thereafter, to subscribe for and purchase from Vivos Therapeutics, Inc., a Delaware corporation , up to [_______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined ...",
"VIVOS THERAPEUTICS, INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT Warrant Shares: [_______] Initial Exercise Date: January [__], 2023 Issue Date: January [__], 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_______]. or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Vivos Therapeutics, Inc., a Delaware corporation , up to [_______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized te...",
"VIVOS therapeutics, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of January 5, 2023, between Vivos Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowle...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership...",
"PLACEMENT AGENCY AGREEMENT Vivos Therapeutics, Inc. Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 A.G.P./Alliance Global Partners 590 Madison Avenue, 28 th Floor 10022",
"Vivos Therapeutics Announces Pricing of $8 Million Private Placement LITTLETON, Colo., Jan. 05, 2023 — Vivos Therapeutics, Inc. , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea and snoring in adults, today announced that it has entered into a definitive agreement with a single institutional investor to raise approximately $8 million in a private placement offering at a price of $1.20 per unit. Each unit consists of one share of common stock and one warrant exercisable for one share common stock at a price of $1.20 per share for a period of five years and 6 months from closing. No actual units will be issued in the offering. After the placement agent fees and estim..." |
|
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/20/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 12/20/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 11/29/2022 |
8-K
| Quarterly results |
| 11/25/2022 |
10-Q/A
| Quarterly Report for the period ended March 31, 2022 [amend] |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
8-K
| Quarterly results |
| 08/26/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/15/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/15/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/14/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|